ISRCTN14442671进行中（未招募）1 期
A Phase I, two-arm, open-label study to evaluate the clinical drug-drug interaction potential of pralsetinib in combination with sensitive transporter substrates, sensitive CYP substrates, or a combined oral contraceptive in patients with advanced or metastatic solid tumors that are not responsive to standard therapies or for which there is no effective therapy
F. Hoffmann-La Roche0 个研究点目标入组 36 人开始时间: 2023年1月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants who are 18 years or more at the time of informed consent
- •2. Eastern Cooperative Oncology Group (ECOG) performance =2
- •3. Participants with histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumours that are not responsive to standard therapies or for which there is no effective therapy
排除标准
- •1. Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant
- •2. Surgery (e.g., stomach bypass) or medical condition that might significantly affect the absorption of medicines (as judged by the investigator)
- •3. History of pneumonitis within the last 12 months
- •4. History of active or latent tuberculosis, regardless of treatment history, or has a positive screening test for latent mycobacterium tuberculosis infection
- •5. Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment
- •6. Cardiovascular issues
- •7. Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease
- •8. Radiotherapy or radiosurgery to any site within 14 days before check-in or more than 30 Gy of radiotherapy to the lung in the 6 months before check-in
- •9. Medical conditions or underlying diseases that constitute contraindications on the use of the substrates or probes used in this study including hypersensitivity to the drugs administered during the study
- •10. Participation in another investigational drug trial within 30 days prior to study drug administration or exposure to more than 3 new investigational agents within 12 months prior to study drug administration
- •11. Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at screening. A negative polymerase chain reaction (PCR) test overrides a positive serological test.
- •12. Human immunodeficiency virus (HIV) antibodies 1/2 at screening
研究者
相似试验
招募中
2 期
A phase II trial to administrate Pembrolizumab for ovarian squamous cell carcinomaovarian squamous cell carcinomaJPRN-jRCT2031220701Yoshihara Kosuke21
撤回
2 期
A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN)AdrenoleukodystrophyNL-OMON51808Poxel S.A.14
进行中（未招募）
1 期
Trial on patients with adrenomyeloneuropathy to assess PXL770's behaviour, a new potential medicine, in the bodyEUCTR2021-006223-18-DEPoxel S.A.24
进行中（未招募）
1 期
Phase II Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients with MET Amplificatioeoplasm malignantMedDRA version: 18.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005696-93-DESanofi-aventis recherche & développement1
进行中（未招募）
1 期
Phase II Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients with MET AmplificatioEUCTR2014-005696-93-FRSanofi-aventis recherche & développement1